Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chiroscience Chirocaine Labeling Cites Possible Safety Advantage

Executive Summary

Approved labeling for Chiroscience's long-acting local anesthetic Chirocaine (levobupivacaine) indicates a possible cardiac and central nervous system safety advantage over bupivacaine based on animal data.

You may also be interested in...

Chirocaine Phase IV Commitments Include Dog Cardiac Resuscitation Study

Celltech Chiroscience Chirocaine (levobupivacaine) Phase IV commitments include the completion of a cardiovascular resuscitation study in dogs. Chirocaine, which cleared FDA August 5 with an indication for surgical anesthesia and pain management in adults, was deemed "approvable" in February.

Zeneca To Divest Chiroscience Shares Following FTC Merger Approval

Zeneca will have to sell its Chiroscience shares under a Federal Trade Commission consent agreement that will allow the company to merge with Astra.

Chirocaine Safety Comparison To Bupivacaine Must Await Resuscitation Data

A safety comparison between Chiroscience/Zeneca's Chirocaine (levobupivacaine) and bupivacaine may depend on resuscitation data, FDA's Anesthetic & Life Support Drugs Advisory Committee members indicated Jan 12.

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts